Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Sanders

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2021
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment responseD R VanDevanter, S L Heltshe, M Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 18, 2020
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatmentD R VanDevanter, S L Heltshe, D B Sanders, et al.
Pediatric Pulmonology|July 12, 2024
Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CFMichael S Schechter, Joshua S Ostrenga, Elizabeth A Cromwell, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 8, 2017
Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosisS L Heltshe, U Khan, V Beckett, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2021
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbationD B Sanders, U Khan, S L Heltshe, et al.
Journal of Autoimmunity|January 1, 2014
Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravisJ S Yi, A Guidon, S Sparks, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 19, 2023
The association between gut microbiome and growth in infants with cystic fibrosisA R Deschamp, Y Chen, W F Wang, et al.
Perfusion|July 12, 2013
The failing Fontan: what's NEXT...?D B Sanders, S R Sowell, S S Park, et al.
Neurology|April 25, 2008
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisD B Sanders, I K Hart, R Mantegazza, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2021
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment responseD R VanDevanter, S L Heltshe, M Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 18, 2020
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatmentD R VanDevanter, S L Heltshe, D B Sanders, et al.
Pediatric Pulmonology|July 12, 2024
Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CFMichael S Schechter, Joshua S Ostrenga, Elizabeth A Cromwell, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 8, 2017
Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosisS L Heltshe, U Khan, V Beckett, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 3, 2021
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbationD B Sanders, U Khan, S L Heltshe, et al.
Journal of Autoimmunity|January 1, 2014
Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravisJ S Yi, A Guidon, S Sparks, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 19, 2023
The association between gut microbiome and growth in infants with cystic fibrosisA R Deschamp, Y Chen, W F Wang, et al.
Perfusion|July 12, 2013
The failing Fontan: what's NEXT...?D B Sanders, S R Sowell, S S Park, et al.
Neurology|April 25, 2008
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisD B Sanders, I K Hart, R Mantegazza, et al.
Pageof 14